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Background: Numerous medications have been tested on patients with pervasive developmental disorder not
otherwise specified (PDD-NOS) and Asperger’s disorder. Although many of these medications have been
demonstrated to be useful, no clear primary treatment for PDD-NOS and Asperger’s disorder has emerged. Despite
the efficacy of some of the medicines, the acceptability and side effects have proven to be barriers to their use.
Recent studies indicate that the traditional Japanese herbal medicine yokukansan (TJ-54) may be safe and useful in
treating behavioral and psychological symptoms in dementia and some neuropsychiatric disorders. We aimed at
evaluating both the efficacy and safety of TJ-54 in patients with well-defined PDD-NOS and Asperger’s disorder.
Methods: This was a 12-week prospective, open-label investigation of TJ-54 in 40 children, adolescents, and adults
diagnosed with PDD-NOS or Asperger’s disorder. Primary outcome measures included the Clinical Global
Impressions-Severity of Illness Scale (CGI-S) and the Aberrant Behavior Checklist-Iritability subscale score (ABC-I).
Results: Forty subjects, ages 8–40 years (mean 22.7 ± 7.3 years) received a mean final TJ-54 dosage of 6.4 ± 1.3 g/
day (range 2.5-7.5 g/day). Full-scale intelligence quotient (IQ) scores ranged from 70 to 110 (mean 88.9 ± 13.2).
Thirty-six (90%) of 40 subjects showed fewer interfering symptoms of irritability, including aggression, self-injury,
and tantrums, with a final CGI-S of 1 or 2 (normal, not at all ill or borderline mentally ill) and a 80% or greater
improvement on the ABC-I. The mean CGI-S score at baseline was 6.8 ± 0.8 whereas scores at end point was 1.9 ±
0.1 (< 0.0001). ABC-I scores ranged from 11 to 29 (mean 17.4 ± 3.66) at baseline, whereas scores at week 12 ranged
from 0 to 5 (mean 0.93 ± 0.97) (p <0.0001). TJ-54 was well tolerated. No subject exited the study due to a
drug-related adverse event.
Conclusions: These preliminary data suggest that TJ-54 may be effective and well tolerated for treatment of severe
irritability, lethargy/withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech in
patients with PDD-NOS or Asperger’s disorder. However, given the characteristics of this trial, the present findings
should be taken cautiously, and larger-scale placebo-controlled studies are needed to elucidate the efficacy and
tolerability of TJ-54 in this understudied population.
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Table 1 Demographic and clinical characteristics of 20
subjects diagnosed with BPD completing a 12-week trial
with YGS
Sociodemographic and clinical variables Value
Sex, N (male/female) 22/18
Age, mean±SD, years 22.7 ± 7.3
IQ 88.9 ± 7.3
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Pervasive developmental disorder not otherwise speci-
fied (PDD-NOS) and Asperger’s disorder are understud-
ied neuropsychiatric disorders characterized by core
social and communication impairments and repetitive
interests and activities [1]. Moreover, severe irritability,
aggression, self-injury, and tantrums are observed fre-
quently and can have a significant impact on the affected
individual and his or her family [2,3]. Despite numerous
treatment studies of autistic disorder (autism), research
focused specifically on the pharmacotherapy of PDD-
NOS and Asperger’s disorder is greatly lacking [4]. Re-
cent epidemiological surveys of PDDs suggest that their
prevalence may be increasing, with conservative esti-
mates of autism at 63.7/10,000, Asperger’s disorder at 6/
10,000, and PDD-NOS at 37.1/10,000 people in the
worldwide [5,6]. These findings have heightened aware-
ness of the various subtypes of PDDs.
The evidence-based practice guideline for the treat-
ment of patients with PDD-NOS and Asperger’s disorder
stresses the role of behavior interventions or psychosocial
treatment as the first-line treatment [4], in combination
with symptom-targeted adjunctive pharmacotherapy [7].
Pharmacotherapy has a relevant role in treating both state
symptoms during periods of acute decompesation and
trait vulnerabilities [8]. Different PDD-NOS and Asper-
ger’s disorder symptom clusters may be responsive to a
range of pharmacological agents. Since the introduction
of atypical antipsychotic drugs, rates of ‘off label’ use for
the treatment of PDD-NOS and Asperger’s disorder have
increased [9-15]. Serotonin reuptake inhibitors and mood
stabilizer are of limited efficacy in patients with PDD-
NOS and Asperger’s disorder [16].
Yokukansan (TJ-54) was developed in 1555 by Xue
Kai as a remedy for restlessness and agitation in children
[17]. Prompted by the increasing life expectancy of the
Japanese population, geriatricians have begun to use this
traditional regimen for behavioral and psychological
symptoms of dementia (BPSD) in the elderly. For
example, Iwasaki et al. reported two cases of BPSD
in an extended care unit that were successfully treated
with TJ-54 [18,19]. Iwasaki et al. reported that TJ-54
improved BPSD and activities of daily living in a rando-
mized, observer-blind, control trial [20]. In this study
subject number is fifty-two patients with mild-to-severe
dementia (Alzheimer’s disease, 30; vascular dementia, 9;
Alzheimer’s disease with CVD; dementia with Lewy bod-
ies, 10). We previously reported that TJ-54 therapy is a
well-tolerated and effective remedy that ameliorates the
symptoms of several neuropsychiatric disorders (border-
line personality disorder, drug-induced tardive dyskin-
esia, schizophrenia, and visual hallucination due to
vision loss) [21-26]. Such detailed case observations and
clinical trials of this traditional Japanese medicinestudied, can suggest new treatments for PDD-NOS and
Asperger’s disorder. TJ-54 extract is a kampo medicine
containing JP Atractylodes lancea rhizome, JP poria
sclerotium, JP Cndium rhizome, JP Uncaria hook, JP
Japanese angelia root, JP Bupleurum root, and JP Glycyr-
rhiza (JP: Japanese Pharmcopoeia). TJ-54 has been used
for the treatment of insomnia, irritability and convulsion
for many years, and the pharmacological effects of TJ-54
is thought to be associated with 5-HT receptors [19,20].
This study aimed to evaluate the efficacy and tolerabil-
ity of TJ-54 in patients with PDD-NOS and Asperger’s
disorder. Our hypothesis was that TJ-54 would reduce
some symptoms of PDD-NOS and Asperger’s disorder,
resulting in improved social and global functioning. This
study should be considered a pilot study permitting the
development of a future randomized comparative study.
Methods
Patient population
Subjects were recruited after a preliminary psychiatric
interview and further assessment at the Outpatient
Community Mental Health Unit of Shimane University
School of Medicine, Izumo, Japan. Subject inclusion cri-
teria were as follows: age > 7 years; diagnosis of PDD-
NOS and Asperger’s disorder according to a structured
clinical interview (SCID I, clinician version) [27] for
DSM-IV criteria; and absence of axis I comorbidity, as
informed by SCID II [28]. Although the score of hyper-
activity are high, in this study, the patients with ADHD
were not included. Patients were excluded if they were
suffering from any major medical or neurological illness,
or pregnant, lactating, or of child-bearing age and not
using adequate contraceptive precautions. Demographic
and clinical characteristics of the sample are listed in
Table 1. This study approved by the Helsinki Committee
(institutional review board) of the Department of Psych-
iatry of the Shimane University School of Medicine. All
patients/guardians provided written informed consent to
participate, and subjects provided written informed assent
when possible, according to institutional guidelines and
the recommendations in the Declaration of Helsinki.
Participants
Forty children, adolescents, and adults 8–40 years were
enrolled. Diagnoses of PDD-NOS or Asperger’s disorder
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ders, 4th edition, Text Revision (DSM-IV-TR) [1] criteria
were made by a board-certified child and adolescent
psychiatrist experienced in the assessment and diagnosis
of PDDs. Subjects were required to have a mental age of
at least 18 months, as determined by the Wechsler
Intelligence Scale [29], and to be physically healthy.
Additional inclusion criteria included a CGI-Severity
(CGI-S) scale [30] score of at least 4 (“moderately iII”)
focused specifically on target symptoms of irritability
(aggression, self-injury, tantrums) and a score >18 on
the ABC [31,32]. Physicians (T.M., T.I., R.W., M. F.)
filled out the ABC scale and CGI-S scale. Subjects with a
DSM-IV-TR diagnosis of another PDD, other primary
psychiatric disorder, active seizure disorder, significant
medical condition, or positive urine pregnancy test were
excluded.
Study design
A 12-week prospective, open-label study design was
chosen to gather pilot data on the effects of TJ-54 in
children, adolescents, and adults with PDD-NOS or
Asperger’s disorder in anticipation of larger-scale,
double-blind, placebo-controlled studies of this popula-
tion. The study duration allowed for gradual titration as
well as a 4-week maintenance phase. All subjects under-
went a screening and baseline visit. Follow-up visits oc-
curred every two weeks during the 12-week open-label
trial period.
Dosage
All subjects initially received 2.5 g/day of TJ-54 for
3 days. The dosage was then increased to 5.0 g/day and
continued to the end of week 2. The investigators then
increased the dosage to maximum of 7.5 g/day over the
next 4 weeks if optimal clinical response had not oc-
curred and intolerable adverse effects had not emerged.
The dosage maintenance phase lasted 8 weeks at the op-
timal dosage.
Nonpharmacologic therapy (e.g., psychotherapy and
behavior modification) was permitted provided, it was
stable before screening and consistent throughout the
study.
Primary outcome measures
The primary outcome measures were the CGI-S and
ABC-I. The CGI-S is a scale designed to assess global
change from baseline. In this study, the rater scored the
CGI-S with regard to severity of irritability, including ag-
gression, self-injury, and tantrums. The CGI-S rates sub-
jects from 1 to 7 (1 = normal, not at all ill; 2 =
borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = mark-
edly ill, 6 = severely ill; and 7 = among the most ex-
tremely ill patients). The ABC was used as a primaryoutcome measure in the aforementioned studies by the
RUPP Autism Network [33,34] and Shea and colleagues
[35]. The ABC is a 58-item checklist that measures six
areas of behavior: irritability, lethargy/withdrawal,
stereotyped behavior, hyperactivity and inappropriate
speech [31,36] and gives a total composite that has con-
firmed reliability and validity in regard to the factor
structure, distribution of scores, and sensitivity to
change. The Irritability subscale consists of 15 items on
temper tantrums, aggression, mood swings, irritability,
property destruction, and self-injury. The CGI-S and
ABC were administered at every visit after baseline.
Patients were rated between 10 AM and noon at base-
line and after 2, 4, 6, 8, 10, and 12 weeks. A videotape of
the subject was obtained, with and without family in
place whenever applicable at clinic, and 3 standardized
clips lasting 15 min were generated while the subject
was rest, talking , and listening. These clips were subse-
quently proposed in random order to four psychiatrist
(T.M., T. I., R.W., and M.F.) with experience in CGI-S
and ABC-I assessment, unaware of the study protocol,
blind to the treatment, who rated all clips in random
order, and the scores for each subject and session were
then averaged. The intraclass correlation coefficient [37]
for total scores, based on 12 randomly selected ratings,
was for 0.81 (P < 0.001) for the ABC-I and 0.83 for the
CGI.
Safety assessment and monitoring
Medical and disease history, physical examination, body
weight, blood pressure, and electrocardiograms were
assessed at baseline. Laboratory studies included a base-
line screening for liver disease, metabolic dysfunction
(ie, glycemia, cholesterol, triglycerides), kidney disease,
electrolyte imbalance, anemia, adequate blood cell and
platelet counts, and prolactin levels. At each visit, a
medical-psychiatric-neurological review was carried out,
together an assessment of body weight and a review
of adverse events and concomitant medications. The
above laboratory studies were reassessed at week 12.
Treatment-emergent adverse events were elicited at each
bi-weekly visit by the treating clinician using the Safety
Monitoring Uniform Report Form, a semistructured
review of body systems [38].
Statistical analysis
All data were expressed as means ± SD. A paired t test
was used to compare the differences between the means
of CGI-S and ABC-I scores before and after treatment.
The Fisher exact test was used to examine the difference
in the proportion of side effects before and after treat-
ment. The statistically significant difference was set a P
< 0.05. Statistical analysis of data was carried out using
SPSS Text Analysis for Surveys 4.0.1.
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Of 50 subjects screened, 40 (80%) met eligibility criteria
and were enrolled. All participants were Japanese. The
sample consisted of 22 males and 18 females, aged 11–
35 years (mean 22.7 ± 7.3 years). Twenty-one subjects
were diagnosed with PDD-NOS, and ninety-one subjects
were diagnosed with Asperger’s disorder. Full-scale
intelligence quotient (IQ) scores ranged from 70 to 110,
with a mean score of 88.9 ± 13.2. Subjects received a
mean final TJ-54 dosage of 6.4 ± 1.3 mg/day (2.5-7.5 g/
day). All subjects completed the study.
Treatment response
Thirty-six (90%) of 40 subjects were considered respon-
ders, as determined by a CGI-S score of 1 or 2 and a >
25% improvement on the ABC-I. All 19 subjects diag-
nosed with Asperger’s disorder responded to treatment,
whereas 17 of 21 (81%) subjects with PDD-NOS
responded. The mean CGI-S score at baseline was 6.8 ±
0.8 whereas scores at end point was 1.9 ± 0.1, with 36
(90%) of 40 subjects rated as much or very much
improved in regards to interfering target symptoms of ir-
ritability (aggression, self-injury, tantrums) (p < 0.0001)
(Figure 1 and Table 2). ABC-I scores ranged from 11 to
29 (mean score 17.4 ± 3.66) at baseline, whereas scores
at week 12 ranged from 0 to 5 (mean score, 1.95 ± 0.7)
(p < 0.001) (Figure 2 and Table 2).
Safety measures and adverse effects
Laboratory parameters were within the normal range at
baseline and remained in the reference range for the
whole sample throughout the 12-week trial. There were
no reports of serious adverse effects attributable to the
study drug. The adverse effects were mild and transient
in five cases (nausea). TJ-54 was well tolerated overall,
with no severe or serious adverse effects recorded during
the study. None of the adverse effects was treatment











Figure 1 Changes in mean CGI-S scores. CGI, Clinical Impressions-SeveriDiscussion
The results of this 12-week prospective, open-label study
suggest that TJ-54 may be effective and well tolerated
for children, adolescents and adults with PDD-NOS and
Asperger’s disorder. Although the drug may also be ef-
fective in patients with PDD-NOS and Asperger’s dis-
order, our small sample size limits interpretation of data
in these PDD subtypes.
In order to clarify the mechanism underlying the
amelioration of aggressiveness by TJ-54, the effects of
this medicine on the aggressive behaviour observed in
rats treated with a serotonegic neurotoxin, para-chlor-
oamphetamine, were investigated. TJ-54 ameliorated the
aggressive behavior as effectively as a serotonin (5-HT)
1A receptor agonist or 5-HT2A receptor antagonist [39].
From these results, we hypothesized that this effect of
TJ-54 may be due to 5-HT1A receptor antagonism [40].
An in vitro binding study demonstrated that TJ-54
showed agonistic binding to 5-HT1A and dopamine
(DA) 2 receptors. A further in vitro binding test to clar-
ify the active compound showed that geissoschzine me-
thyl ether (GM), an alkaloid in uncaria hook, a galencial
constituent of TJ-54, had a similar potent binding to 5-
HT1A and DA2 receptors [25,41,42].
Treatment with TJ-54 at dosages from 2.5 to 7.5 g/day
associated with significant amelioration of irritability, in-
cluding aggression, self-injury, tantrums, lethargy,
stereotypy, hyperactivity, and inappropriate speech. In
light of research suggesting that a disregulation of DA
and 5-HT contributes to maladaptive behavior in PDDs
[43], TJ-54’s unique mechanism of action as a partial D2
agonist, 5-HT1A agonist, and 5-HT2A antagonist [25],
may prove important for both its effectiveness and toler-
ability in PDD-NOS and Asperger’s disorder.
The significant reduction on the ABC-I subscale from
baseline to end point is noteworthy in that the subjects
in this study had higher baseline irritability subscale
scores than those in the RUPP Autism Network study of




Table 2 Baseline score and group change in behavior after treatment with TJ-54 for 12 weeks
Baseline Group 12-week Group Group Mean p1
Baseline Group 12-week Group Group Mean p1
Measure Mean SD Mean SD Mean SD
CGI-S 6.78 0.83 1.95 0.11 -4.825 0.46 <.0001
ABC-I (Irritability) 17.4 3.66 0.925 0.971 -16.5 1.46 <.0001
ABC-Total 77.8 11.4 6.90 4.84 -70.9 5.21 <.0001
Lethargy 23.7 3.68 2.10 1.87 -21.6 1.78 <.0001
Stereotypy 9.23 3.78 1.33 1.37 -7.90 1.55 <.0001
Hyperactivity 21,7 3.90 1.83 1.89 -19.9 1.67 <.0001
Inappropriate speech 5.78 1.25 0.73 0.75 -5.05 0.631 <.0001
1 Significance by t test.
2 Negative values indicate a positive change.
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autism, such as PDD-NOS, often suffer from a signifi-
cant degree of similar symptomatology [44].
Although highly speculative, these positive changes in
socialization may be due to TJ-54’s mechanism of action
as a partial 5-HT1A agonist [25]. A putative association
has been hypothesized between partial agonism at 5-
HT1A receptors and improvements in anxiety and de-
pression, as well as the negative symptoms of schizo-
phrenia [24]. Thus, it is possible that TJ-54 targets these
symptoms, thereby potentially resulting in subjects’
increased ability and/or interest in interacting with
others. It also may be that by decreasing irritability, the
children and adolescents were better able to improve
their social functioning over time. Overall, TJ-54 was
well tolerated, with no severe or serious adverse effects
associated with the drug.
The preliminary results of this study suggest that TJ-
54 has the potential to be an effective and well-tolerated
treatment for severe irritability in pediatric patients with
PDD-NOS, and possibly in Asperger’s disorder. PDD or
autism spectrum disorder, range from a severe form,













Figure 2 Changes in mean ABC scores. ABC, Aberrant Behavior checklistprevious studies almost AD and PDD-NOS children
were not mentally retarded (high-functioning). To re-
duce the bias by heterogeneity of the PDD, in this study,
we include mild form PDD, AD and PDD-NOS, and ex-
clude moderate or severe form of PDD, autism.
Limitations
Given the design characteristics of this trial, the present
findings should be taken cautiously. Study limitations in-
clude its open design, lack of a control group, and small
sample size. In an open-label study, both placebo effects
and the role of previously prescribed medication prior to
wash out cannot be ruled out as explanations for the
observed improvement. Furthermore, regression to the
mean is a ubiquitous phenomenon in repeated data that
should always be considered as a possible cause of an
observed change [45]. However, the rapid improvement
in symptoms over several weeks observed here is con-
sistent with a response related to therapeutic dosages of
TJ-54. In this study, diagnoses were made by child and
adolescent psychiatrist experienced in the diagnosis of
PDDs using DSM-IV-TR criteria. However, it will be im-
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of individuals with subtypes of PDDs, such as the Aut-
ism Diagnostic Interview-Revised [46]. Finally, one
might consider this sample as not completely represen-
tative of the whole population of PDD-NOS and Asper-
ger’s disorder clients because only outpatients not
suffering at present from axis I disorders were included,
and no subjects had IQ below 70. On the other hand,
PDD-NOS and Asperger’s disorder is a heterogeneous
condition, and given the present small sample size, treat-
ment efficacy data were better interpreted in a sample
that was as homogeneous as possible. In summary, our
trial suggests that TJ-54 therapy is a well-tolerated and
effective remedy that improves the symptoms of PDD-
NOS and Asperger’s disorder. This study has several
limitations that could potentially impact the reliability
and validity of these findings. Because of its open-label
design, bias as well as a placebo effect could be a factor
in our findings of improvement in irritability, as well as
having provided socialization opportunities to these rela-
tively high functioning individuals every 2 weeks. The
number of subjects in this study was relatively small. In
addition, the absence of a control group limits the con-
clusions that can be definitively drawn regarding the
safety and tolerability of TJ-54 in this population.
Conclusions
Although at present there is little evidence of advantages
of one antipsychotic over another, the present findings
would suggest that TJ-54 is suitable for several symp-
toms. Present data need to be confirmed in larger, ran-
domized, double-blind trials.
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